GlassScriptPhysician profile
Andrew S O Connor
NPI 1679581326
$7,353.30
in general payments reported to CMS, 2019-2025
17 companies · $6,579 in 2025
The $6,579 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.86 · 2021: $33.23 · 2022: $239 · 2023: $199 · 2024: $220 · 2025: $6,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,628 · Consulting Fee: $2,400 · Food and Beverage: $1,905 · Education: $64.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,628.45 |
| Consulting Fee | $2,400.00 |
| Food and Beverage | $1,904.64 |
| Education | $64.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $5,966.98 | 2025 | Optiflux |
| Amgen INC. | $206.25 | 2019-2025 | Tavneos |
| Outset Medical INC | $171.12 | 2023 | |
| Novartis Pharmaceuticals Corporation | $137.65 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $112.96 | 2025 | Jynarque |
| Nxstage Medical, INC. | $112.61 | 2022 | |
| Calliditas Therapeutics US INC. | $101.89 | 2024-2025 | Tarpeyo |
| Organogenesis INC. | $100.68 | 2024 | |
| Akebia Therapeutics INC | $87.09 | 2019-2025 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $76.76 | 2019-2025 | Farxiga, Lokelma |
| Scpharmaceuticals INC. | $54.79 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.97 | 2025 | Jardiance |
| Genzyme Corporation | $45.09 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.61 | 2025 | |
| Ardelyx, INC. | $28.55 | 2025 | Ibsrela |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $28.22 | 2023 | Korsuva, Veltassa |
| Apellis Pharmaceuticals, INC. | $27.08 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew O Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.